BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22841436)

  • 21. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
    Raheem IT; Schreier JD; Fuerst J; Gantert L; Hostetler ED; Huszar S; Joshi A; Kandebo M; Kim SH; Li J; Ma B; McGaughey G; Sharma S; Shipe WD; Uslaner J; Vandeveer GH; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
    Bioorg Med Chem Lett; 2016 Jan; 26(1):126-32. PubMed ID: 26602277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia.
    Layton ME; Kern JC; Hartingh TJ; Shipe WD; Raheem I; Kandebo M; Hayes RP; Huszar S; Eddins D; Ma B; Fuerst J; Wollenberg GK; Li J; Fritzen J; McGaughey GB; Uslaner JM; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2023 Jan; 66(2):1157-1171. PubMed ID: 36624931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.
    Macek TA; Suzuki K; Asin K; Kimura H
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):524-532. PubMed ID: 32598478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.
    Ho GD; Yang SW; Smotryski J; Bercovici A; Nechuta T; Smith EM; McElroy W; Tan Z; Tulshian D; McKittrick B; Greenlee WJ; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1019-22. PubMed ID: 22222034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
    Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
    Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
    Raheem IT; Breslin MJ; Fandozzi C; Fuerst J; Hill N; Huszar S; Kandebo M; Kim SH; Ma B; McGaughey G; Renger JJ; Schreier JD; Sharma S; Smith S; Uslaner J; Yan Y; Coleman PJ; Cox CD
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5903-8. PubMed ID: 22892116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.
    Świerczek A; Jankowska A; Chłoń-Rzepa G; Pawłowski M; Wyska E
    Curr Drug Targets; 2019; 20(16):1652-1669. PubMed ID: 31368871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.
    Rzasa RM; Hu E; Rumfelt S; Chen N; Andrews KL; Chmait S; Falsey JR; Zhong W; Jones AD; Porter A; Louie SW; Zhao X; Treanor JJ; Allen JR
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7371-5. PubMed ID: 23149228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.
    Yang SW; Smotryski J; McElroy WT; Tan Z; Ho G; Tulshian D; Greenlee WJ; Guzzi M; Zhang X; Mullins D; Xiao L; Hruza A; Chan TM; Rindgen D; Bleickardt C; Hodgson R
    Bioorg Med Chem Lett; 2012 Jan; 22(1):235-9. PubMed ID: 22142545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors.
    Hu E; Kunz RK; Rumfelt S; Chen N; Bürli R; Li C; Andrews KL; Zhang J; Chmait S; Kogan J; Lindstrom M; Hitchcock SA; Treanor J
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2262-5. PubMed ID: 22365755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening.
    Al-Nema M; Gaurav A; Akowuah G
    Comput Biol Chem; 2018 Dec; 77():52-63. PubMed ID: 30240986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
    Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
    Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PDE10A inhibitors: novel therapeutic drugs for schizophrenia.
    Kehler J; Nielsen J
    Curr Pharm Des; 2011; 17(2):137-50. PubMed ID: 21355834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
    Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
    Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
    Vlasceanu A; Jessing M; Kilburn JP
    Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
    Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
    Kulkarni SS; Patel MR; Talele TT
    Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.
    Asproni B; Murineddu G; Pau A; Pinna GA; Langgård M; Christoffersen CT; Nielsen J; Kehler J
    Bioorg Med Chem; 2011 Jan; 19(1):642-9. PubMed ID: 21087867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update.
    Kehler J
    Expert Opin Ther Pat; 2013 Jan; 23(1):31-45. PubMed ID: 23210904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.